Phase II Trial of First-Line Durvalumab and Chemotherapy in Patients With Extra-Pulmonary Small Cell Carcinoma

Introduction: Prospective randomized trials are lacking in extensive-stage or metastatic extra-pulmonary small cell carcinoma (EPSCC). As a result, treatment for EPSCC is largely extrapolated from SCLC studies. Methods: This single-arm phase II trial enrolled patients with EPSCC to investigate the a...

詳細記述

書誌詳細

主要な著者:	Peey-Sei Kok, PhD, Bryan Chan, MMed (Clin Epi), Mason Aberoumand, MAppStat, Alison Zhang, PhD, Ken O’Byrne, MD, Subotheni Thavaneswaran, PhD, Frank Lin, PhD, Maya Kansara, PhD, Theresa Corpuz, BSc (Hons), Patrick Wheeler, BS, Robert John Simes, PhD, David Thomas, PhD, Chee Khoon Lee, PhD
フォーマット:	Artigo
言語:	Inglês
出版事項:	Elsevier 2026-07-01
シリーズ:	JTO Clinical and Research Reports
主題:	Small cell Durvalumab Chemo-immunotherapy Extrapulmonary small cell carcinoma EPSCC
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S2666364326000652
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!